Sten from Finland

Registered at the short selling broker Skilling, 4 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Arrowhead Pharmaceuticals, Inc (ARWR) shares information

Arrowhead Pharmaceuticals, Inc.

24h Change

1.38 %


Live rate: Market closed

Stock data per Friday 25 Sep, 2020

0.61 (+ 1.38%)
US Market is closed

Live Stock price in graph for Arrowhead Pharmaceuticals, Inc. (ARWR)

  • Latest Volume

    847,541 (-1.32 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high


  • Today low


  • 52 week high


  • 52 week low


  • YTD Change


Quick links

Broker recommendations for Arrowhead Pharmaceuticals, Inc

The Arrowhead Pharmaceuticals, Inc stock is rated at 1.25 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Friday 21 August, 2020 by a total of 10 brokers. This means that the consensus of the 10 different brokers is leaning toward to buy/moderate buy.

0 (0%)
0 (0%)
2 (20%)
1 (10%)
7 (70%)

Price target by analysts

The 10 latest analyst estimates, per Wednesday 16 September, 2020, show the following high, low and average price targets.
Target Average: 65.1 USD
Target High: 90 USD
Target Low: 31 USD


Latest news about Arrowhead Pharmaceuticals, Inc.

Below you can find the most recent news posts about Arrowhead Pharmaceuticals, Inc., primarily from US and UK based news sources.

Arrowhead Pharmaceuticals News: Why ARWR Stock Is Shooting 45% Higher Today

Wednesday, 16 September 2020, 19:54:01
Arrowhead Pharmaceuticals (ARWR) news for Wednesday includes positive interim results from a clinical trial pushing ARWR stock higher.
— InvestorPlace

Why Arrowhead Pharma’s Stock Is Trading Higher Today

Wednesday, 16 September 2020, 13:20:00
Arrowhead Pharmaceuticals (NASDAQ: ARWR) shares are trading higher on Wednesday after the company announced positive interim 24-week liver biopsy results in …
— Benzinga

Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences

Tuesday, 8 September 2020, 13:30:00
PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Arrowhead Pharmaceuticals to present at multiple investor conferences in September 2020
— Business Wire

Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020

Monday, 31 August 2020, 10:50:00
PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Arrowhead Pharmaceuticals positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates ARO-APOC3 and ARO-ANG3 at ESC Congress
— Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

Tuesday, 18 August 2020, 13:30:00
PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Arrowhead dosed the first patient in a clinical trial of RNAi based ARO-HIF2 for treatment of renal cell carcinoma
— Business Wire